Whether PDE4 inhibitors exert their therapeutic effects on Th2-asthma by regulating the immunogenic features of DCs remains to be clearly defined, although one study showed that the modulation of cAMP levels in DCs reduced Th2 development and airway inflammation in a bronchial asthma model [130] (Table 2). This evidence concerns the gene PDE4A and asthma.